Navigation Links
Celsion Corporation Provides Business Update
Date:4/23/2013

LAWRENCEVILLE, N.J., April 23, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today is providing a business update, including the latest findings from its analysis of clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  Celsion is evaluating ThermoDox® in a Phase III clinical trial for primary liver cancer (the HEAT Study), a Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer.

Phase III HEAT Study Data Analysis 

The Company has conducted a comprehensive analysis of the data from the Phase III HEAT Study with key principal investigators, data experts and liver cancer experts.  This follows the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the study's primary endpoint.  Emerging data from the HEAT Study post analysis demonstrates that ThermoDox® markedly improves progression free survival (PFS) and overall survival (OS) in patients who had optimal RFA.  The analysis indicates that if patients' lesions undergo RFA for 45 minutes or more, they clearly benefitted from ThermoDox®.  These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients.  This data is subject to further verification and review by the HEAT Study Steering Committee. 

"We have completed a thorough review of the HEAT Study and there is clear evidence that ThermoDox® can benefit patients when RFA is optimized," said Dr. Nicholas Borys , Celsion's Vice President and Chief Medical Officer.  "These data are very exciting and consistent with the mechanism of ThermoDox&
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celsion Corporation Announces $15 Million Registered Direct Offering
2. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
5. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
6. Neogen Corporation Announces 2nd Quarter Results Conference Call
7. Luminex Corporation to Present at JP Morgan Healthcare Conference
8. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
9. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
10. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
11. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Pittsburgh, PA (PRWEB) January 15, 2014 The ... Company, publisher of Food Safety Tech , an e-Journal ... has signed an agreement for the second year for the ... with Pittcon 2014. The partnership provides that the registration fee ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... MONICA, Calif., Oct. 9 Aida,Pharmaceuticals, Inc. ... China,s,leading pharmaceutical companies, today announced that the ... sale of Etimicin,sulfate throughout China. Aida expects ... to increase noticeably as sales efforts are,pursued ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... company, today announced that it intends to ... Food and Drug Administration,(FDA) for its innovative, ... "After reviewing the data from our recently ...
... Pharmaceutical and biotech,companies reach much greater and sustained ... and marketing, balancing therapeutic,innovation with commercial focus in ... companies to break down the walls that have ... strengths of both,talented medical researchers and skillful marketers. ...
Cached Biology Technology:Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted 2Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 2Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 3Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 4Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 5Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 6Pharmaceutical Product Launch: Commercially Focused R&D Increases Drug's Market Potential 2
(Date:4/21/2014)... which is commonly used as a farm soil fertilizer, ... genes from the cows, gut bacteria. The findings, reported ... the American Society for Microbiology, hints that cow manure ... resistance genes that transfer to bacteria in the soils ... resistance (AR) genes have already been identified, but the ...
(Date:4/21/2014)... Dallas have received a federal grant to investigate ... of many everyday products might affect human health. ... and Dr. Rockford Draper, professor of molecular and ... from the National Institute of Environmental Health Sciences, ... track how multi-walled carbon nanotubes interact with human ...
(Date:4/21/2014)... Professor Lawrence Krauss was honored at the Academia ... to public understanding of science and for his ... The Academia Film Olomouc award for Outstanding Communication ... on April 19, in Olomouc, Czech Republic. , ... of science documentary films, and the largest such ...
Breaking Biology News(10 mins):Cow manure harbors diverse new antibiotic resistance genes 2Cow manure harbors diverse new antibiotic resistance genes 3Grant to fund research on possible cell contaminants 2Grant to fund research on possible cell contaminants 3Lawrence Krauss is honored at international festival of science documentary films 2Lawrence Krauss is honored at international festival of science documentary films 3
... (Edmonton) Two University of Alberta researchers have published a step ... harmful chemicals on commercial crops by developing plants that produce ... biologist Allen Good says the energy required to produce nitrogen ... a $100 billion a year. Good says that while they ...
... adelgid, has been marching north along the Appalachians, killing almost ... forests in Georgia, Tennessee, and Virginia. The pest recently arrived ... only extreme cold stops the adelgid. But now a ... "fungal microfactory" technology that promises to give forest managers and ...
... joint meeting of the International Ethological Conference (IEC) and ... more than 1,100 researchers from around the world for ... Included among the speakers will be one of ... head of the Department of Ethology at the Etvs ...
Cached Biology News:Forest fungus factory 2Behavior 2011 to draw global contingent of more than 1,100 animal researchers to IU next week 2